ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

アロチノロール

Arotinolol

HCID 2239
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
52560-77-7
標準SMILES
CC(C)(C)NCC(O)CSc1nc(-c2ccc(C(N)=O)s2)cs1
InChIKey
BHIAIPWSVYSKJS-UHFFFAOYSA-N
分子式
C15H21N3O2S3
平均分子量
371.5 g/mol
単同位体質量
371.07959044

概要

Arotinolol is a member of thiophenes and an aromatic amide.

名称と識別子

優先名称
Arotinolol
IUPAC
5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamide
現地名
アロチノロール
英語名
AROTINOLOL
分子式
C15H21N3O2S3
分子量
371.54

名称と別名

Arotinolol68377-92-4ArotinololumNSC-317940394E3P3B99DTXSID3022619S-5965-(2-{[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl}-1,3-thiazol-4-yl)thiophene-2-carboxamide5-(2-((3-(tert-butylamino)-2-hydroxypropyl)sulfanyl)-1,3-thiazol-4-yl)thiophene-2-carboxamideRefChem:1141612-(3'-tert-Butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole hydrochlorideDTXCID302619
名称をさらに表示
rac-5-[2-[[(R*)-3-[(1,1-ジメチルエチル)アミノ]-2-ヒドロキシプロピル]チオ]-4-チアゾリル]-2-チオフェンカルボアミドアロチノロールrac-5-[2-[[(R*)-3-(tert-ブチルアミノ)-2-ヒドロキシプロピル]チオ]チアゾール-4-イル]チオフェン-2-カルボアミド5-[2-[[3-(tert-ブチルアミノ)-2-ヒドロキシプロピル]チオ]チアゾール-4-イル]チオフェン-2-カルボアミド5-(2-{[3-(tert-ブチルアミノ)-2-ヒドロキシプロピル]スルファニル}-1,3-チアゾール-4-イル)チオフェン-2-カルボキサミドArotinoloArololArot-APIArottnololNSC 317940Arotinolol (Almarl)Arotinolol free baseAROTINOLOL USP/EP/BPArotinolol Intermediate
5-(2-((3-((1,1-Dimethylethyl)amino)-2-hydroxypropyl)thio)-4-thiazolyl)-2-thiophenecarboxamide5-(2-((3-(tert-Butylamino)-2-hydroxypropyl)thio)thiazol-4-yl)thiophene-2-carboxamideArotinolol [INN]Arotinololum [Latin](+-)-Arotinolol5-[2-[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl-1,3-thiazol-4-yl]thiophene-2-carboxamideUNII-394E3P3B99MFCD00865895

物性

構造計算による物性補完中

XLogP
2.3
極性表面積
170 Ų
水素結合供与体数
3
水素結合受容体数
7
回転可能結合数
8
重原子数
23
形式電荷
0
複雑度
406

実験および物理化学的性質

SolubilitySlightly soluble
Boiling Point599ºC at 760 mmHg
Melting Point149-153ºC

物理化学的性質

融点
148 · 148-149°
沸点
599.8 · 599.8±60.0 °C(Predicted)
比重(密度)
1.35 · 1.35
貯蔵温度
2 · 2-8°C(protect from light)
溶解性
DMSO(微量)、メタノール(微量)
酸解離定数(Pka)
13.71 · 13.71±0.20(Predicted)
外見
個体
色
オフホワイトからペールイエロー

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

安全データ

注意喚起語
警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302

化学と産業

薬理情報

Protein Binding · 1 件

The stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. Arotinolol is highly bound to serum proteins reaching a ratio of the original dose of 95.3% in the form of the R-enantiomer and 84.5% of the S-enantiomer. The presented stereospecificity is thought to be related to the α1-acid glycoprotein.

Pharmacodynamics · 1 件

Preclinical studies showed a lack of intrinsic sympathomimetic activities or membrane-establishing properties. It is confirmed that arotinolol presents vasorelaxant activity. This characteristic is also proved to be mainly mediated by its α1-blocking property. In preclinical hypertension trials, there is a specific acute bradycardiac and antihypertensive activity with a pronounced reduction in heart rate. Some reports indicate a delayed development of hypertension when arotinolol is administered daily. Arotinolol has a dose-dependent decrease in cardiac contractility and coronary blood flow as well as an increase in total peripheral resistance. The effects of arotinolol have been confirmed in clinical trials where this drug was able to decrease cardiac index and thus, blood pressure.

Mechanism of Action · 1 件

Arotinolol binds to the β1-, β2- and α1- adrenergic receptor sites with a very high affinity. Radioligand studies have shown that arotinolol presents a higher affinity to the β-receptor compared to the α-receptor. The elucidated mechanism of action seems to be the result of a reduction in the cardiac output via the β-blockade and an additional inhibition of the counter-regulatory increase in peripheral resistance mediated by the α-blockade.

Biological Half-LifeThe reported half-life of arotinolol is 7.2 hours.
Metabolism/MetabolitesThe stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. The R-enantiomer remains unchanged and it is eliminated from the organism by urine in this form while the S-enantiomer is metabolized.
MeSH Pharmacological Classification · 2 件

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
52560-77-7、68377-92-4
PubChem CID
2239
DTXSID
DTXSID3022619
ChEMBL
CHEMBL93298
ChEBI
CHEBI:135569
UNII
394E3P3B99
Nikkaji
J239.627K

Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.

Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.

Absorption, Distribution and Excretion · 3 件

Arotinolol gets rapidly absorbed and distributed in the plasma. The plasma concentration peaks 2 hours after initial administration.

The stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. Both of the enantiomers were found in urine, suggesting this as the major elimination pathway. It is possible to find arotinolol in urine 2-4 hours after initial administration.

The stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. The S-enantiomer is highly retained in red blood cells. The distribution studies have shown that arotinolol is mainly distributed from the plasma to the liver followed by the lungs and lastly in the heart. The distribution in the liver was independent on the stereochemistry of the molecules.

上流・下流製品情報

上流原料

水酸化ナトリウム